IP Library Granted Patent US 11,240,995
Granted Patent B2
US 11,240,995 · App. 16/409,656 · Granted Feb 8, 2022

Genetically modified non-human animal with human or chimeric TIM-3

Inventors: Yuelei Shen (Beijing, CN); Jian Ni (Beijing, CN); Yanan Guo (Beijing, CN); Rui Huang (Beijing, CN); Meiling Zhang (Beijing, CN); Lei Zhao (Beijing, CN); Yang Bai (Beijing, CN)
Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
A01K67/0271A01K67/0278A01K2227/105A01K2267/0331
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,240,995
App. No.
16/409,656
Granted
Feb 8, 2022
Kind
B2
Abstract

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.

Claims (20)

1. A genetically-modified mammal whose genome comprises a chimeric TIM-3 gene at an endogenous TIM-3 locus, wherein the chimeric TIM-3 gene comprises a nucleic acid encoding a portion of an extracellular domain of a human TIM-3 protein in place of a nucleic acid encoding a corresponding portion of an extracellular domain of an endogenous TIM-3 protein, wherein the chimeric TIM-3 gene is operably linked to an endogenous TIM-3 promoter, wherein the mammal expresses a chimeric TIM-3 protein encoded by the chimeric TIM-3 gene, wherein the mammal is a mouse, a rat, or a non-human primate.

2. The mammal of claim 1 , wherein the mammal is a mouse and the chimeric TIM-3 gene comprises a sequence that encodes an amino acid sequence that is at least 95% identical to SEQ ID NO:30.

3. The mammal of claim 1 , wherein the chimeric TIM-3 gene comprises a sequence that encodes amino acids 22-128 of SEQ ID NO:26.

4. The mammal of claim 1 , wherein the mammal is a non-human primate.

5. The mammal of claim 1 , wherein the mammal is a mouse.

6. The mammal of claim 1 , wherein the mammal does not express endogenous TIM-3.

7. The mammal of claim 1 , wherein the mammal is homozygous with respect to the chimeric TIM-3 gene.

8. The mammal of claim 1 , wherein the mammal further comprises a sequence encoding an additional human or chimeric protein.

9. The mammal of claim 8 , wherein the additional human or chimeric protein is programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Lymphocyte Activating 3 (LAG-3), B And T Lymphocyte Associated (BTLA), Programmed Cell Death 1 Ligand 1 (PD-L1), TNF Receptor Superfamily Member 9 (4-1BB), CD27, CD28, CD47, T-Cell Immunoreceptor With Ig And ITIM Domains (TIGIT), CD27, Glucocorticoid-Induced TNFR-Related Protein (GITR), or TNF Receptor Superfamily Member 4 (OX40).

10. The mammal of claim 1 , wherein the portion of the extracellular region of the human TIM-3 protein comprises at least 50 amino acid residues of the extracellular region of the human TIM-3 protein.

11. The mammal of claim 1 , wherein the portion of the extracellular region of the human TIM-3 protein comprises at least 80 amino acid residues of the extracellular region of the human TIM-3 protein.

12. The mammal of claim 1 , wherein the chimeric TIM-3 gene comprises a nucleic acid encoding the entire extracellular domain of the human TIM-3 protein in place of a nucleic acid encoding the entire extracellular domain of the endogenous TIM-3 protein.

13. The mammal of claim 1 , wherein the chimeric TIM-3 gene comprises a sequence that encodes an amino acid sequence that is identical to SEQ ID NO: 30.

14. A genetically-modified, non-human mammal whose genome comprises a nucleic acid sequence encoding a chimeric TIM-3 protein at an endogenous TIM-3 gene locus, wherein the chimeric TIM-3 protein comprises a humanized TIM-3 extracellular region and an endogenous TIM-3 cytoplasmic region, and the nucleic acid sequence encoding the chimeric TIM-3 protein is operably linked to an endogenous TIM-3 promoter, wherein the mammal expresses the chimeric TIM-3 protein, and wherein the mammal is a mouse, rat, or non-human primate.

15. The mammal of claim 14 , wherein the humanized TIM-3 extracellular region comprises at least 50 amino acid residues of the extracellular region of the human TIM-3 protein.

16. The mammal of claim 14 , wherein the nucleic acid sequence encodes an amino acid sequence that is at least 95% identical to SEQ ID NO: 30.

17. The mammal of claim 14 , wherein the mammal is a mouse.

18. The mammal of claim 14 , wherein the humanized TIM-3 extracellular region comprises at least 80 amino acid residues of the extracellular region of the human TIM-3 protein.

19. The mammal of claim 14 , wherein the mammal is a rat.

20. The mammal of claim 14 , wherein the mammal does not express endogenous TIM-3.

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2021
From: BEIJING BIOCYTOGEN CO., LTD
To: BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Reel/Frame 055087/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2019
From: SHEN, YUELEI; NI, JIAN; GUO, YANAN; HUANG, RUI; ZHANG, MEILING; ZHAO, LEI; BAI, YANG
To: BEIJING BIOCYTOGEN CO., LTD.
Reel/Frame 050605/0277 →
Priority Claims (2)
CN 201610994218.2 · Nov 11, 2016 · national
CN 201711103773.2 · Nov 10, 2017 · national
Continuity (2)
Continuation PCTCN2017110494 · Nov 10, 2017
Related Publication 20190357506A1 · Nov 28, 2019